Reactivity of anti-macrophage monoclonal antibody D11 in human leukemia and malignant lymphoma

production and characterization of new anti-human cd20 monoclonal antibody

the b-cell cd20 antigen is one of the most reliable surface targets in immunotherapy of b lymphoma. in this project, we studied the production and characterization of a new monoclonal antibody against chimeric human cd20 extra loops (hcd20 exl). the results showed that clone c12h, igg2/k isotype reacted with the antigen in elisa and immunoblot. the kd value was  found to be 2×10-9m and flow cyt...

Monoclonal Antibody Therapy of T-Cell Leukemia and Lymphoma

T-cell leukemias and lymphomas are a heterogeneous group of uncommon tumors that account for 7-15% of lymphomas. [1] They represent approximately 6,500 new cases annually in the United States. Typically patients with malignant T-cell disorders present with highgrade lesions, advanced stage disease and have systemic or “B” symptoms at diagnosis. Until relatively recently these diseases were trea...

Monoclonal antibody-based therapies of leukemia and lymphoma.

http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Information abo...

Monoclonal antibody SN10 which shows a highly selective reactivity with human B leukemia-lymphoma and is effectively internalized into cells.

The monoclonal antibody termed SN10 (IgG1-k) which was generated and characterized in the present study shows a highly selective reactivity with fresh (uncultured) human leukemia-lymphoma cells. The antigen defined by SN10 is a cell surface glycoprotein composed of a single polypeptide chain of Mr 36,000 and designated as gp36. The primary reactivity of SN10 is against mature B-lineage leukemia...

Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody